Stock Scorecard
Stock Summary for VBI Vaccines Inc (VBIV) - $0.60 as of 4/25/2024 9:29:37 PM EST
Total Score
9 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for VBIV
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for VBIV
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for VBIV
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for VBIV
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for VBIV
Financial Details for VBIV
Company Overview |
|
---|---|
Ticker | VBIV |
Company Name | VBI Vaccines Inc |
Country | USA |
Description | VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company is headquartered in Cambridge, Massachusetts. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 3/31/2024 |
Next Earnings Date | 5/13/2024 |
Stock Price History |
|
Last Day Price | 0.60 |
Last Day Price Updated | 4/25/2024 9:29:37 PM EST |
Last Day Volume | 123,624 |
Average Daily Volume | 752,590 |
52-Week High | 3.47 |
52-Week Low | 0.45 |
Last Price to 52 Week Low | 33.33% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 101.20 |
Sector PE | 61.73 |
5-Year Average PE | -148.09 |
Free Cash Flow Ratio | 0.72 |
Industry Free Cash Flow Ratio | 12.66 |
Sector Free Cash Flow Ratio | 30.74 |
Current Ratio Most Recent Quarter | 0.48 |
Total Cash Per Share | 0.83 |
Book Value Per Share Most Recent Quarter | 0.32 |
Price to Book Ratio | 0.82 |
Industry Price to Book Ratio | 5.66 |
Sector Price to Book Ratio | 22.08 |
Price to Sales Ratio Twelve Trailing Months | 2.02 |
Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.16 |
Share Statistics |
|
Total Shares Outstanding | 28,432,300 |
Market Capitalization | 17,059,380 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.62% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 18.06% |
Reported EPS 12 Trailing Months | -6.03 |
Reported EPS Past Year | -0.01 |
Reported EPS Prior Year | -9.29 |
Net Income Twelve Trailing Months | -92,836,000 |
Net Income Past Year | -92,836,000 |
Net Income Prior Year | -113,303,000 |
Quarterly Revenue Growth YOY | 191.10% |
5-Year Revenue Growth | 31.92% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 23,685,000 |
Total Cash Past Year | 23,685,000 |
Total Cash Prior Year | 62,629,000 |
Net Cash Position Most Recent Quarter | -27,084,000 |
Net Cash Position Past Year | -27,084,000 |
Long Term Debt Past Year | 50,769,000 |
Long Term Debt Prior Year | 48,888,000 |
Total Debt Most Recent Quarter | 50,769,000 |
Equity to Debt Ratio Past Year | 0.13 |
Equity to Debt Ratio Most Recent Quarter | 0.13 |
Total Stockholder Equity Past Year | 7,527,000 |
Total Stockholder Equity Prior Year | 64,163,000 |
Total Stockholder Equity Most Recent Quarter | 7,527,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.00 |
MACD Signal | 0.01 |
20-Day Bollinger Lower Band | 0.52 |
20-Day Bollinger Middle Band | 0.62 |
20-Day Bollinger Upper Band | 0.71 |
Beta | 1.92 |
RSI | 49.42 |
50-Day SMA | 1.14 |
200-Day SMA | 48.41 |
System |
|
Modified | 4/25/2024 2:08:39 PM EST |